Review

Does Combination Therapy with Statins and Fibrates Prevent Cardiovascular Disease in Diabetic Patients with Atherogenic Mixed Dyslipidemia?

Aris P. Agouridis, Christos V. Rizos, Moses S. Elisaf, Theodosios D. Filippatos

Manuscript submitted March 24, 2013; resubmitted May 20, 2013; accepted May 20, 2013.

Keywords: cardiovascular disease, type 2 diabetes, dyslipidemia, fibrate, HDL cholesterol, statin, triglycerides

Abstract

Type 2 diabetes mellitus (T2DM) is associated with the development and progression of cardiovascular disease (CVD). Statins have an established efficacy in the management of dyslipidemia primarily by decreasing the levels of low-density lipoprotein cholesterol and thus decreasing CVD risk. They also have a favorable safety profile. Despite the statin-mediated benefit of CVD risk reduction a residual CVD risk remains, especially in T2DM patients with high triglyceride (TG) and low high-density lipoprotein cholesterol (HDL-C) values. Fibrates decrease TG levels, increase HDL-C concentrations, and improve many other atherosclerosis-related variables. Fibrate/statin co-administration improves the overall lipoprotein profile in patients with mixed dyslipidemia and may reduce the residual CVD risk during statin therapy. However, limited data exists regarding the effects of statin/fibrate combination on CVD outcomes in patients with T2DM. In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study the statin/fibrate combination did not significantly reduce the rate of CVD events compared with simvastatin/placebo in patients with T2DM. However, it did show a possible benefit in a pre-specified analysis in the subgroup of patients with high TG and low HDL-C levels. Furthermore, in the ACCORD study the simvastatin/fenofibrate combination significantly reduced the rate of progression of retinopathy compared with statin/placebo administration in patients with T2DM. The present review presents the available data regarding the effects of statin/fibrate combination in patients with T2DM and atherogenic mixed dyslipidemia.

Fulltext: HTML , PDF (600KB)

This article has been cited by other articles:

	Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies Tsimihodimos V, Filippatos TD, Elisaf MS Expert Opin Drug Metab Toxicol 2017. 13(4):399-408
	Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy Tarantino N, Santoro F, De Gennaro L, Correale M, Guastafierro F, Gaglione A, Di Biase M, Brunetti ND Vasc Health Risk Manag 2017. 13:29-41
	Paraoxonase 1 Activity, Lipid Profile, and Atherogenic Indexes Status in Coronary Heart Disease Cheraghi M, Shahsavari G, Maleki A, Ahmadvand H Rep Biochem Mol Biol 2017. 6 (1):1-7
	Pitavastatin and carbohydrate metabolism: what is the evidence? Filippatos TD, Elisaf MS Expert Rev Clin Pharmacol 2016. 9(7):955-960
	Controversy of oral hypoglycemic agents in type 2 diabetes mellitus: Novel move towards combination therapies Ghadge AA, Kuvalekar AA Diabetes Metab Syndr 2016. In press
	Diabetes mellitus and cardiovascular risk: Working group recommendations of Diabetes and Cardiovascular Disease of the Spanish Society of Diabetes Arrieta F, Iglesias P, Pedro-Botet J, Tebar FJ, Ortega E, Nubiola A, Pardo JL, Maldonado GF, Obeya JC, Matute P, Petrecca R, Alonso N, Sarabia E, Sanchez-Margalet V, Aleman JJ, Navarro J, Becerra A, Duran S, Aguilar M, Escobar-Jimenez F, Grupo de Trabajo Diabetes y Enfermedad Cardiovascular de la Sociedad Espanola de Diabetes (SED) Aten Primaria 2016. 48(5):325-336
	Emerging Potential of Natural Products as an Alternative Strategy to Pharmacological Agents Used Against Metabolic Disorders Dias TR, Bernardino RL, Meneses MJ, Sousa M, Sa R, Alves MG, Silva BM, Oliveira PF Curr Drug Metab 2016. 17(6):582-597
	Comparison of efficacy and safety of choline fenofibrate (fenofibric acid) to micronized fenofibrate in patients of mixed dyslipidemia: A randomized, open-label, multicenter clinical trial in Indian population Patel P, Barkate H Indian J Endocrinol Metab 2016. 20(1):67-71
	The Atherogenic Dyslipidemia Ratio Log (Tg)/Hdl-C Was Not Associated with Urinary Albumin Excretion Rate (Uaer) and Increased Cardiovascular Risk in Black Patients with Type 2 Diabetes Kajingulu MF, Lepira BF, Mbutiwi IN, Makulo JR, Bieleli E, Nseka MN World J Cardiovasc Dis 2016. 6(1):14-20
	New Fixed-Dose Combinations of Fenofibrate/Simvastatin Therapy Significantly Improve the Lipid Profile of High-Risk Patients with Mixed Dyslipidemia Versus Monotherapies Foucher C, Aubonnet P, Reichert P, Berli M, Schaeffer A, Calvo Vargas CG, Lochocka A, Belenky D, Koch HF, Cholib study Investigators Cardiovasc Ther 2015. 33(6):329-337
	Peroxisome Proliferator-Activated Receptor α in Lipid Metabolism and Atherosclerosis Yu XH, Zheng XL, Tang CK Adv Clin Chem 2015. 71:171-203
	Safety considerations with fenofibrate/simvastatin combination Filippatos TD, Elisaf MS Expert Opin Drug Saf 2015. 14(9):1481-1493
	Diabetes mellitus and cardiovascular risk: Working group recommendations of Diabetes and Cardiovascular Disease of the Spanish Society of Diabetes Arrieta F, Iglesias P, Pedro-Botet J, Tebar FJ, Ortega E, Nubiola A, Pardo JL, Maldonado GF, Obeya JC, Matute P, Petrecca R, Alonso N, Sarabia E, Sanchez-Margalet V, Aleman JJ, Navarro J, Becerra A, Duran S, Aguilar M, Escobar-Jimenez F, Grupo de Trabajo Diabetes y Enfermedad Cardiovascular de la Sociedad Espanola de Diabetes (SED) Clin Investig Arterioscler 2015. 27(4):181-192
	The Role of PCSK9 in Lipid Metabolism: Clinical Relevance to Treating Cardiac Disease Han Y, Willis MS J Cardiol Ther 2015. 2(5):393-399
	The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors Filippatos TD, Athyros VG, Elisaf MS Exp Opin Drug Metabol Toxicol 2014. 10(6):787-812
	Adverse Effects of GLP-1 Receptor Agonists Filippatos TD, Panagiotopoulou TV, Elisaf MS Rev Diabet Stud 2014. 11(3-4):202-230
	Dapagliflozin in patients with type 2 diabetes mellitus Filippatos TD, Liberopoulos EN, Elisaf MS Ther Adv Endocrinol Metab 2014. In press